| Name | Title | Contact Details |
|---|
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases.
More than an OEM company, IntriCon is invested in creating a hearing healthcare system to offer individuals hearing help at a cost they can afford.
It`s all about the experience. Everything we do is about simplifying and making things better and easier. It`s about making a difference in people`s lives.
Zydus Pharmaceuticals (USA) is a Pennington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.